Prospective randomized control trial for Helicobacter pylori eradication by vonoprazan.

Prospective randomized control trial for Helicobacter pylori eradication by vonoprazan. - Study of Helicobacter pylori eradication.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020419

Enrollment

100

Registered

2016-03-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Helicobacter pylori eradication by vonoprazan(40mg/day) and AMPC(1500m/day). 7days Helicobacter pylori eradication by vonoprazan(40mg/day), AMPC(1500m/day), and CAM(800mg/day). 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of Helicobacter pylori infection.

Exclusion criteria

Exclusion criteria: Exclusion criteria included of other gastric ulcer drug, or penicillin allergy, or heart failure, or hepatic failure, or renal failure, or pregnancy.

Design outcomes

Primary

Measure	Time frame
Successful rate of Helicobacter pylori eradication.	—

Countries

Japan

Contacts

Public ContactShigenaga Matsui

Kinki university hospital gastroenterology

ma2i@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026